Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + envafolimab + recombinant human endostatin
- Development stage
- Unknown
- Lead developer
- Hebei Medical University
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
This therapeutic regimen involves the combination of an immune checkpoint inhibitor—either the PD-1 inhibitor camrelizumab or the PD-L1 inhibitor envafolimab—with recombinant human endostatin (Endostar). Camrelizumab is a humanized IgG4 monoclonal antibody that blocks the interaction between PD-1 and its ligands, while envafolimab is a unique subcutaneous single-domain antibody (nanobody) targeting PD-L1. Recombinant human endostatin is an anti-angiogenic agent that inhibits vascular endothelial growth and tumor angiogenesis by interfering with endothelial cell migration and survival. This combination is being investigated by Hebei Medical University for the treatment of leptomeningeal metastases in patients with lung cancer, aiming to improve survival outcomes by leveraging the synergistic effects of immune checkpoint blockade and anti-angiogenesis in the central nervous system microenvironment.
- Other names
- Camrelizumab or envafolimab plus Endostatin for Lung Cancer Leptomeningeal Metastasis
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)GPC1 (Glypican-1)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on camrelizumab + envafolimab + recombinant human endostatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + envafolimab + recombinant human endostatin.